{"id":"W2985333121","doi":"10.1093/eurheartj/ehz809","title":"Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"Esperion Therapeutics; Idorsia Pharmaceuticals; Daiichi Sankyo Europe; Servier; Belvoir Media Group; Medicines Company; Regado Biosciences; Novo Nordisk; Daiichi-Sankyo; AstraZeneca; Amarin Corporation; Luitpold Pharmaceuticals; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Amgen; Pfizer; Bayer HealthCare; Sanofi; American Heart Association","keywords":"Medicine; Alirocumab; Internal medicine; Acute coronary syndrome; Cardiology; Intensive care medicine; Myocardial infarction; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002453706,0.0008468465,0.002026465,0.0003162086,0.0002310588,0.0007802849,0.0003630175,0.0004972552,0.002224274],"category_scores_gemma":[0.003770909,0.0003024251,0.003361525,0.0003200687,0.0003515691,0.0006131007,0.0008645345,0.001134141,0.0001133919],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004996905,"about_ca_system_score_gemma":0.0006977405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003664666,"about_ca_topic_score_gemma":0.007914177,"domain_scores_codex":[0.9988361,0.0006976537,0.00008960717,0.00017946,0.00009787975,0.00009930658],"domain_scores_gemma":[0.9985091,0.0005132286,0.000453959,0.0001320863,0.0001474849,0.0002440674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8343478,0.001823672,0.06633598,0.004529634,0.03633621,0.0001675762,0.0002695674,0.001843218,0.002470051,0.0005421246,0.003906049,0.04742805],"study_design_scores_gemma":[0.5618901,0.03570114,0.3304845,0.0009485856,0.05455286,0.0004584412,0.0002873796,0.007881271,0.001157811,0.001799356,0.00470515,0.0001334316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846944,0.01120011,0.0005576157,0.0005164568,0.0001022749,0.0002702944,0.001605529,0.00003035133,0.001022861],"genre_scores_gemma":[0.9950984,0.001883924,0.0006800651,0.0004287371,0.00008396005,0.0002803158,0.0009981125,0.000006792995,0.0005396241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003664666,"threshold_uncertainty_score":0.01297659,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02351587982491802,"score_gpt":0.3218050398897973,"score_spread":0.2982891600648792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}